全文获取类型
收费全文 | 3167篇 |
免费 | 144篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 60篇 |
儿科学 | 67篇 |
妇产科学 | 30篇 |
基础医学 | 610篇 |
口腔科学 | 50篇 |
临床医学 | 168篇 |
内科学 | 684篇 |
皮肤病学 | 11篇 |
神经病学 | 538篇 |
特种医学 | 57篇 |
外科学 | 448篇 |
综合类 | 4篇 |
预防医学 | 68篇 |
眼科学 | 24篇 |
药学 | 182篇 |
中国医学 | 2篇 |
肿瘤学 | 314篇 |
出版年
2023年 | 14篇 |
2022年 | 23篇 |
2021年 | 31篇 |
2020年 | 17篇 |
2019年 | 15篇 |
2018年 | 42篇 |
2017年 | 38篇 |
2016年 | 44篇 |
2015年 | 45篇 |
2014年 | 44篇 |
2013年 | 64篇 |
2012年 | 105篇 |
2011年 | 146篇 |
2010年 | 77篇 |
2009年 | 79篇 |
2008年 | 133篇 |
2007年 | 163篇 |
2006年 | 173篇 |
2005年 | 175篇 |
2004年 | 193篇 |
2003年 | 211篇 |
2002年 | 254篇 |
2001年 | 79篇 |
2000年 | 72篇 |
1999年 | 82篇 |
1998年 | 70篇 |
1997年 | 65篇 |
1996年 | 48篇 |
1995年 | 57篇 |
1994年 | 44篇 |
1993年 | 48篇 |
1992年 | 51篇 |
1991年 | 65篇 |
1990年 | 38篇 |
1989年 | 48篇 |
1988年 | 40篇 |
1987年 | 35篇 |
1986年 | 41篇 |
1985年 | 33篇 |
1984年 | 36篇 |
1983年 | 24篇 |
1982年 | 26篇 |
1981年 | 18篇 |
1979年 | 15篇 |
1978年 | 18篇 |
1976年 | 18篇 |
1975年 | 18篇 |
1974年 | 20篇 |
1973年 | 20篇 |
1968年 | 17篇 |
排序方式: 共有3317条查询结果,搜索用时 17 毫秒
51.
52.
Masaki Ri Kenshi Suzuki Tadao Ishida Junya Kuroda Taku Tsukamoto Takanori Teshima Hideki Goto Carolyn C. Jackson Huabin Sun Lida Pacaud Ei Fujikawa TzuMin Yeh Tomoyoshi Hatayama Kensuke Aida Yoshihiro Sunagawa Shinsuke Iida 《Cancer science》2022,113(12):4267
Chimeric antigen receptor (CAR) T cells targeting B‐cell maturation antigen have shown positive responses in patients with multiple myeloma (MM). The phase 2 portion of the CARTITUDE‐1 study of ciltacabtagene autoleucel (cilta‐cel) included a cohort of Japanese patients with relapsed/refractory MM. Following a conditioning regimen of cyclophosphamide (300 mg/m2) and fludarabine (30 mg/m2), patients received a single cilta‐cel infusion at a target dose of 0.75 × 106 (range, 0.5–1.0 × 106CAR‐positive viable T cells/kg). The primary endpoint was overall response rate (ORR; defined as partial response or better) by International Myeloma Working Group criteria. A key secondary endpoint was the rate of very good partial response (VGPR) or better (defined as VGPR, complete response, stringent complete response). This first analysis was performed at 6 months after the last patient received cilta‐cel. Thirteen patients underwent apheresis, nine of whom received cilta‐cel infusion. Eight patients who received cilta‐cel at the target dose responded, yielding an ORR of 100%. Seven of eight (87.5%) patients achieved a VGPR or better. One additional patient who received a below‐target dose of cilta‐cel also achieved a best response of VGPR. MRD negativity (10−5 threshold) was achieved in all six evaluable patients. Eight of nine (88.9%) patients who received cilta‐cel infusion experienced a grade 3 or 4 adverse event, and eight (88.9%) patients experienced cytokine release syndrome (all grade 1 or 2). No CAR‐T cell neurotoxicity was reported. A positive benefit/risk profile for cilta‐cel was established for heavily pretreated Japanese patients with relapsed or refractory MM. 相似文献
53.
Tetsuo Sekine Kyoichiro Tsuchiya Hiroyuki Uchinuma Sayaka Horiuchi Megumi Kushima Sanae Otawa Hiroshi Yokomichi Kunio Miyake Yuka Akiyama Tadao Ooka Reiji Kojima Ryoji Shinohara Zentaro Yamagata The Yamanashi Adjunct Study of the Japan Environment Childrens Study Group 《Journal of diabetes investigation.》2022,13(8):1444
Gestational diabetes mellitus (GDM) is one of the most common pregnancy‐related complications; it is associated with adverse pregnancy outcomes and metabolic disorders in offspring, consistent with the concept of the developmental origins of health and disease. This cohort study of women without diabetes (n = 761), who were part of the Yamanashi Adjunct Study of the Japan Environment and Children’s Study, aimed to explore the associations between maternal GDM and their offspring’s level of high‐sensitivity C‐reactive protein (hsCRP), a biomarker of inflammatory and cardiovascular diseases. We analyzed the associations between GDM and the offspring’s hsCRP levels using a multiple logistic regression model. A mother with GDM significantly increased the risk for high hsCRP level by 4.07‐fold (≥2.0 mg/L) in the child. As such, maternal GDM was significantly associated with increased serum hsCRP levels in 8‐year‐old children. 相似文献
54.
Tadao Nakazawa Tetsuo Kondo Eiichi Sato Utaroh Motosugi Dongfeng Niu Kunio Mochizuki Tomonori Kawasaki Tetsu Yamane Ryohei Katoh 《Journal of cutaneous pathology》2015,42(11):897-902
Porocarcinoma is a rare malignancy with glandular adnexal differentiation. A 38‐year‐old Japanese man noticed a subcutaneous mass in right inguinal region about 20 years prior to being examined. Radiological examinations demonstrated the mass, 11 × 10 cm in size, was in the subcutaneous fat tissue. Recently, the mass grew rapidly, and it was biopsied by an orthopedist based on clinical diagnosis of primary soft tissue tumor. Histopathological examination of the resected specimens also revealed that the tumor lacked involvement to the skin. Microscopically, the tumor was mainly composed of poroid cells with partially obvious squamous differentiation, accompanied by focal ductal structures immunoreactive for CEA and EMA. The tumor contained a low‐grade area consisting of poroid cells and high‐grade area with squamous differentiation. This histopathological heterogeneity suggested malignant transformation from poroma. The patient had the tumor in almost same size over the period of 20 years, which is the longest in the previous reports. This unique case of subcutaneous porocarcinoma is reported. 相似文献
55.
This review examines some of the advances in understanding myoclonus over the last 25 years. The classification of myoclonus into cortical, brainstem, and spinal forms has been consolidated, each with distinctive clinical characteristics and physiological mechanisms. New genetic causes of myoclonus have been identified, and the molecular basis of several of these conditions has been discovered. It is increasingly apparent that disease of the cerebellum is particularly important in the genesis of cortical reflex myoclonus. However, the precise mechanism and origin of myoclonus in many situations remain uncertain. Effective treatment of myoclonus remains limited, and the challenge lies ahead to develop more therapeutic options. © 2011 Movement Disorder Society 相似文献
56.
Hidetoshi Naito Yasuo Mastsuda Tadao Yorozu Kohtaro Shiomi Toshiaki Maeda Kohzabro Seki Toshihiko Tada Hideo Fujii 《Clinical cardiology》1991,14(8):644-650
The systemic hemodynamic and coronary dilative responses to sublingual nitroglycerin were studied in patients receiving transdermal nitroglycerin. A total of 48 patients with coronary artery disease were divided into 4 groups: 12 patients receiving 1 tablet of sublingual nitroglycerin without transdermal nitroglycerin (Group 1), 12 patients receiving 1 tablet of sublingual nitroglycerin with 12-hour-daily intermittent therapy of transdermal nitroglycerin (Group 2), 12 patients receiving 1 tablet of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 3), and 12 patients receiving 2 tablets of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 4). Before and during administration of sublingual nitroglycerin, aortic pressure, left ventricular pressure, and coronary artery diameter were examined at diagnostic cardiac catheterization in all patients. During sublingual nitroglycerin, the decreases of aortic systolic pressure and left ventricular end-diastolic pressure were greater in Group 1, 2, and 4 than in Group 3. Dilation of coronary arteries by sublingual nitroglyerin tended to be greater in Group 1, 2, and 4 than in Group 3. Thus, the effects of sublingual nitroglycerin for the relief of ischemia might be more prominent in patients with intermittent therapy of transdermal nitroglycerin than in those with continuous therapy. The increased dose of sublingual nitroglycerin for the relief of ischemia might be more effective in patients with continuous therapy of transdermal nitroglycerin. 相似文献
57.
Shiratori Y Kato N Yoshida H Nakata R Ihori M Imazeki F Yokosuka O Kawase T Katamoto T Unuma T Nakamura A Ikegami F Hirota K Omata M 《Digestive diseases and sciences》2000,45(3):565-574
Adequate dosing of interferon (IFN) and its cost-effectiveness for sustained virological response were evaluated in relation to viral load and subtype. Prospective analysis of IFN therapy on 326 patients with chronic hepatitis C free from cirrhosis was performed using 9 or 6 million unit (MU) of IFN for six months daily and/or three times a week. Sustained virological response was achieved in 50–94% of patients with 2 × 104 copies/ml (competitive RT-PCR) or <100 × 103 copies/ml (Amplicor monitor) of HCV RNA by 468–1206 MU of IFN, but response was only 0–25% of the patients with 2 × 105.5 copies/ml (competitive RT-PCR) or >200 × 103 copies/ml (Amplicor monitor), even with 468–1206 MU of IFN. A high sustained rate was demonstrated in patients with 100–200 × 103 copies/ml of HCV RNA by 901–1206 MU of IFN, in comparison to that with 900 MU of IFN. Multivariate analysis showed that IFN dose had a significant value for the efficacy of IFN therapy in patients presenting 100–200 × 103 copies/ml of HCV RNA. Cost efficacy analysis indicated that it cost approximately $10,000, $26,000, and $50,000–227,000 for one person-viral eradication in the patients with <100, 100–200, and >200 × 103 copies/ml, respectively. High-dose IFN is only cost effective in patients with intermediate viral loads, and IFN therapy could be recommended in patients with <200 × 103 copies/ml of HCV RNA. 相似文献
58.
59.
60.